strains have been associated with slower clinical responses to fluoroquinolones and treatment failures, clinical laboratories should attempt to identify these isolates (3, 6, 7) . However, despite the accumulation of clinical, microbiologic, and pharmacokietic-pharmacodynamic studies suggesting a resistance breakpoint of >0.125 μg/mL for ciprofloxacin, the clinical breakpoints published by the Clinical and Laboratory Standards Institute (CLSI) (susceptibility <1 μg/mL, resistance >4 μg/mL) and those from the antibiogram committee of the French Society for Microbiology (CA-SFM) (susceptibility <0.5 μg/mL, resistance >1 μg/mL) (www.sfm.asso.fr/nouv/general.php?pa=2) have not been reevaluated (6) (7) (8) (9) were compared with those of Salmonella Typhi strain Ty2 (GenBank accession no. AE014613).
In subpopulation A, 75 isolates had wild-type QRDR sequences, whereas 2 isolates had a gyrB mutation at codon 465 leading to amino acid substitution Gln to Leu. Their Nal MICs were 2 and 4 μg/mL, respectively, and those of Cip were 0.04 μg/mL and 0.08 μg/mL, respectively. Notably, both isolates were acquired in Mexico during 1998 and 2009, respectively. In subpopulation C, the lowest MIC values for Cip (0.06 μg/mL) were associated with a mutation at codon 87 of the gyrA gene, whereas MICs did not increase with the additional mutation in the parE gene. Eleven isolates of subpopulation B were categorized as susceptible to Nal by determining MICs and by using CLSI breakpoints (susceptibility, <16 μg/mL; resistance, >32 μg/mL). (5) were performed. On the strength of the results, we concluded that the gyrB mutation was acquired independently by strains belonging to different PFGE types (Figure 2 ). According to a newly developed single nucleotide polymorphism assay (Y.S.), 2 of these strains belong to the current emerging H58 Asian population (4), whereas the others do not ( however, the effects of this mutation need to be formally demonstrated by site-directed mutagenesis. Furthermore, the involvement of an efflux system, such as AcrAB-TolC and OqxA, or the qnrC gene, have not been investigated and cannot be excluded.
Whatever the molecular mechanism of resistance of such strains, the main concern is detection of such isolates in clinical practice to prevent fluoroquinolone treatment failures.
Consequently, the Nal R screening test should no longer be recommended and ciprofloxacin drug MICs should be determined for all Salmonella Typhi isolates instead. There is also a clear need to reevaluate the clinical breakpoints for this pathogen. on the basis of PFGE fingerprinting. Similarity analysis was performed by using the Dice coefficient, and clustering was done by using the unweighted pair-group method with arithmetic averages.
